Weatherall Institute of Molecular Medicine

Vagus nerve stimulation reduces inflammation in children with Inflammatory Bowel Disease, Feinstein Institutes study finds

Retrieved on: 
Wednesday, October 18, 2023
Research, Managed Care, General Health, Consumer, Medical Devices, Children, Science, Biotechnology, Neurology, Practice Management, Other Science, Health, Abdominal pain, Child, MRI, Medical research, Feinstein, Inflammation, Feinstein Institutes for Medical Research, Cohen, FC, Vagus nerve, Weatherall Institute of Molecular Medicine, Heart rate, Diarrhea, Human, Medicine, Prevalence, Vagus nerve stimulation, Incontinence, Diabetes, Rheumatoid arthritis, MBA, Electricity, TENS, Bleeding, GE Research, Ulcerative colitis, Multimedia, Northwell Health, Disease, Clinical trial, Nature Communications, Pulmonary hypertension, Neuroscience, Ear, Arthritis, IBD, Sickle Cell Anemia, a Molecular Disease, Credit, Molecular medicine, Brain, Cancer, Patient, Liver disease, Biomedical engineering, Bangladesh Technical Education Board, MS, Central nervous system, Lupus, Medical imaging, Pharmaceutical industry, Management, Gastroenterology, MD

View the full release here: https://www.businesswire.com/news/home/20231018401966/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231018401966/en/
    The Feinstein Institutes for Medical Research’s Dr. Benjamin Sahn led the vagus nerve stimulation clinical trial.
  • Inflammation and the inflammatory reflex – the neuronal signaling between the brain and body – is an important immune response.
  • Previous research and functional MRI studies have mapped stimulation of the auricular branch of the vagus nerve to activate the same brain regions as implanted devices, confirming this nerve as a suitable non-invasive target to administer vagus nerve stimulation.
  • Also, Feinstein Institutes researchers, in collaboration with GE Research, published research that harnessed ultrasound technology to reduce inflammation in the body non-invasively.

Feinstein Institutes’ Elmezzi Graduate School class of 2023 physician-scientists conferred

Retrieved on: 
Tuesday, May 30, 2023
Health, Hospitals, Health Technology, Health Insurance, Clinical Trials, Research, Science, VNS, Oncology, University, MD–PhD, Frontiers, University of Calgary, Feinstein Institutes for Medical Research, Nature Communications, Biomedical Research, DRS, Vagus nerve stimulation, Haemophilia, Multimedia, Medicine, Doctor of Philosophy, Cumming School of Medicine, Molecular medicine, Student, Patient, Physician, Weatherall Institute of Molecular Medicine, Thomas, Medical research, Nursing, Management, Elmezzi Graduate School of Molecular Medicine, MD, Immunology

The 2023 Commencement Exercises for the Elmezzi Graduate School of Molecular Medicine took place on May 25 at The Feinstein Institutes for Medical Research , where three graduate students were conferred with their PhD.

Key Points: 
  • The 2023 Commencement Exercises for the Elmezzi Graduate School of Molecular Medicine took place on May 25 at The Feinstein Institutes for Medical Research , where three graduate students were conferred with their PhD.
  • (Photo: Business Wire)
    The Elmezzi Graduate School of Molecular Medicine is a PhD program for physicians who wish to pursue careers in biomedical research.
  • The Elmezzi Graduate School of Molecular Medicine is supported in part by a generous endowment from The Thomas and Jeanne Elmezzi Foundation.
  • “The Elmezzi Graduate School of Molecular Medicine is a unique program that transforms physicians into physician-scientists,” said Annette T. Lee, PhD , dean of the Elmezzi Graduate School of Molecular Medicine.

Feinstein Institutes’ Advancing Women in Science and Medicine breaks $1M funding record during annual event

Retrieved on: 
Thursday, May 18, 2023
Managed Care, Fund Raising, General Health, Philanthropy, Hospitals, Science, Consumer, Clinical Trials, Biotechnology, Health, Other Philanthropy, Other Science, Research, Other Health, Women, Pharmaceutical, Oncology, Diamond, Lymphoma, Autoimmune disease, Education, Chronic lymphocytic leukemia, Teaching, Feinstein Institutes for Medical Research, Cancer, Woman, Multimedia, Mentorship, Northwell Health, Maureen, Doctor of Philosophy, Maternal health, Molecular medicine, Lincoln, Impossible, AWSM, Hospital, Patent, Ruth, Weatherall Institute of Molecular Medicine, Faculty, Elliot, Credit, Medical research, Pharmaceutical industry, Management, MD, Medicine

Now in its 13th year, the Feinstein Institutes for Medical Research’s Advancing Women in Science and Medicine (AWSM – pronounced “awesome”) awards luncheon raised a record-breaking $1 million in funding to support medical research conducted by women scientists.

Key Points: 
  • Now in its 13th year, the Feinstein Institutes for Medical Research’s Advancing Women in Science and Medicine (AWSM – pronounced “awesome”) awards luncheon raised a record-breaking $1 million in funding to support medical research conducted by women scientists.
  • View the full release here: https://www.businesswire.com/news/home/20230518005523/en/
    This year’s Advancing Women in Science and Medicine annual luncheon raised a record-breaking $1 million in funding to support medical research and women scientists at the Feinstein Institutes and across Northwell Health.
  • This year’s event was held on May 3 at Lincoln Center’s new David Geffen Hall, where women scientists at the Feinstein Institutes and across Northwell Health received 69 awards.
  • Donors fully fund the gifts; this year, six $50,000 Emerging Science Awards and 13 $25,000 Career Development Awards were handed out.

Hoag's Pickup Family Neurosciences Institute Selected to Participate in Revolutionary Clinical Trial for the Prevention of Alzheimer's Disease

Retrieved on: 
Thursday, March 2, 2023
Memory, Safety, Research, Ron, Weatherall Institute of Molecular Medicine, PET, University, Patient, University of California, Irvine Medical Center, Alzheimer's disease, Risk, Molecular medicine, Foundation for the National Institutes of Health, Disease, Hope, Biomarker, National Institute on Aging, Ageing, Hoag, Brain, Pharmaceutical industry, Medical imaging, Vaccine

NEWPORT BEACH, Calif., March 2, 2023 /PRNewswire/ -- Hoag's Pickup Family Neurosciences Institute has started enrolling participants for a Phase 1 clinical trial evaluating the safety and tolerability of a first-of-its-kind Alzheimer's disease vaccine. The hope is that the vaccine will eventually be used to prevent Alzheimer's disease in healthy people who are at risk.

Key Points: 
  • NEWPORT BEACH, Calif., March 2, 2023 /PRNewswire/ -- Hoag's Pickup Family Neurosciences Institute has started enrolling participants for a Phase 1 clinical trial evaluating the safety and tolerability of a first-of-its-kind Alzheimer's disease vaccine.
  • The hope is that the vaccine will eventually be used to prevent Alzheimer's disease in healthy people who are at risk.
  • Hoag is the only site in California among total six sites in the United States selected to participate in the study.
  • Hoag's Pickup Family Neurosciences Institute is currently offering many other Alzheimer's clinical trials.

Feinstein Institutes researcher discovers potential therapeutic target for lethal sepsis

Retrieved on: 
Friday, February 3, 2023
Managed Care, Research, General Health, Pharmaceutical, Infectious Diseases, Hospitals, University, Education, Publishing, Clinical Trials, Science, Communications, Health, Weatherall Institute of Molecular Medicine, Mouse, Infection, Science Advances, Patient, Septic, Credit, Shock, Inflammation, Feinstein Institutes for Medical Research, Medical research, Death, Molecular medicine, Disease, Bacteria, Multimedia, Drug discovery, COVID-19, Medicine, Immunosuppression, Doctor of Philosophy, MD, Pharmaceutical industry, Vaccine, Sepsis

Scientists from the Feinstein Institutes for Medical Research recently published in Science Advances the discovery of a novel protein that could be a potential therapeutic target for lethal sepsis.

Key Points: 
  • Scientists from the Feinstein Institutes for Medical Research recently published in Science Advances the discovery of a novel protein that could be a potential therapeutic target for lethal sepsis.
  • (Credit: Feinstein Institutes)
    Affecting nearly 50 million people worldwide, sepsis occurs when the body’s immune system triggers excessive inflammation in an attempt to help fight against infections.
  • The new study, led by Feinstein Institutes’ Haichao Wang, PhD, focuses on finding protein mediators that may contribute to uncontrolled immune responses to lethal infections.
  • Last year, Dr. Wang earned the Shock Society’s 2021 Scientific Achievements Award for his years of commitment and contribution to sepsis research.

Feinstein Institutes lupus researchers recognized with top honors

Retrieved on: 
Thursday, November 17, 2022
Research, Hospitals, Other Health, Biotechnology, Managed Care, General Health, Pharmaceutical, Health, Science, Other Science, Diamond, Medicine, Behavior, NAS, Brain, Autoimmune disease, Lupus, Friends, Molecular medicine, Hofstra University, Feinstein Institute for Medical Research, DRS, Medical research, American College of Rheumatology, Multimedia, American College, Donald, National academy, Science, Doctor of Philosophy, Autoantibody, Cancer, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Maureen, Research, MBBS, Degenerative disease, Northwell Health, ACR, Inflammation, Master, Genetics, Mental health, National Academy of Sciences, Autoimmunity, Education, Weatherall Institute of Molecular Medicine, College, Cognition, Hope, Patient, Antibody, Management, Pharmaceutical industry, Rheumatology, MD

Anne Davidson (left) and Betty Diamond received top honors from the American College of Rheumatology (ACR) and the Association of Rheumatology Professionals.

Key Points: 
  • Anne Davidson (left) and Betty Diamond received top honors from the American College of Rheumatology (ACR) and the Association of Rheumatology Professionals.
  • Dr. Diamond is the director of the Institute of Molecular Medicine at the Feinstein Institutes and a pioneer in the basic science research of autoimmune diseases, particularly systemic lupus erythematosus.
  • The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State.
  • Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine.

EQS-News: Kizoo invests in Rejuvenation Startup Mogling Bio

Retrieved on: 
Friday, October 28, 2022
Molecular medicine, Interstitial lung disease, Cincinnati, Lift, Weatherall Institute of Molecular Medicine, Investor, Cancer, Investment, Mentorship, CEO, Leukemia, Rejuvenation, Senior, University of Ulm, CDC42, Hematology, Technology, Degenerative disease, Immune system, Ageing, Research, B cell, Neurological disorder, VC, Institute, Vaccine, Pharmaceutical industry

Berlin/Ulm, Germany - October 26, 2022 Mogling Bio, a privately held biotech company, announces today that it has successfully completed its first seed investment round.Sole investor is venture capital firm Kizoo Technology Capital, a rejuvenation biotech investor focusedonstartups reversing age-related damage on a cellular and molecular level.

Key Points: 
  • Berlin/Ulm, Germany - October 26, 2022 Mogling Bio, a privately held biotech company, announces today that it has successfully completed its first seed investment round.Sole investor is venture capital firm Kizoo Technology Capital, a rejuvenation biotech investor focusedonstartups reversing age-related damage on a cellular and molecular level.
  • Mogling Bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system.
  • Our approach has particular potential in treating diseases of the blood system and improving the immune system, said Dr.Jrgen Reess, CEO of Mogling Bio.
  • Mogling Bio Inc. is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system.

Kizoo invests in Rejuvenation Startup Mogling Bio

Retrieved on: 
Wednesday, October 26, 2022
Molecular medicine, Interstitial lung disease, Cincinnati, Lift, Weatherall Institute of Molecular Medicine, Investor, Cancer, Investment, Mentorship, CEO, Leukemia, Rejuvenation, Senior, University of Ulm, CDC42, Hematology, Technology, Degenerative disease, Immune system, Ageing, Research, GLOBE, B cell, Neurological disorder, VC, Institute, Vaccine, Pharmaceutical industry

Mogling Bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system.

Key Points: 
  • Mogling Bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system.
  • Our approach has particular potential in treating diseases of the blood system and improving the immune system, said Dr.Jrgen Reess, CEO of Mogling Bio.
  • Mogling Bio Inc. is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system.
  • Treated cells can perform their tasks again in a juvenile way, and thereby contribute to both, the rejuvenation of stem cells and the immune system.

Endometriosis Researchers One Step Closer to Diagnosing Condition With Menstrual Blood

Retrieved on: 
Thursday, September 15, 2022
Science, Practice Management, Research, Managed Care, General Health, Health, Hospitals, Genetics, Feinstein Institute for Medical Research, Institute, Northwell Health, Molecular medicine, Trial of the century, Gregersen, Woman, Autoimmunity, MD, Biomarker, Research, Credit, Infertility, LinkedIn, Weatherall Institute of Molecular Medicine, DRS, Patient, Endometriosis, Clinical trial, Genetics, Cancer, Mental health, CEO, Pain, Metz, Medical research, Doctor of Philosophy, Uterus, Diagnosis, Science, ROSE, B cell, Medicine, Multimedia, Disease, BMC Medicine, Medical device, Pharmaceutical industry, Medical imaging

Since 2016, scientists at The Feinstein Institutes for Medical Research have studied the genetic and cellular makeup of menstrual blood or menstrual effluent (ME) to diagnose endometriosis.

Key Points: 
  • Since 2016, scientists at The Feinstein Institutes for Medical Research have studied the genetic and cellular makeup of menstrual blood or menstrual effluent (ME) to diagnose endometriosis.
  • Peter Gregersen and Christine Metz are co-directors of the Research OutSmarts Endometriosis (ROSE) clinical study.
  • The condition affects one in 10 reproductive-age females, resulting in chronic, often debilitating pain or infertility and other medical complications.
  • Due to the lack of non-surgical diagnostic tools, it can often take seven to 10 years to be diagnosed with endometriosis.

Feinstein Institutes Researchers Identify Potential Drug to Treat Sepsis

Retrieved on: 
Monday, August 29, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, CEO, Cancer, Research, DRS, Mass, Northwell Health, Genetics, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Feinstein Institute for Medical Research, Norepinephrine, Science, Death, Food and Drug Administration, Molecular medicine, Pediatric Critical Care Medicine, Credit, Infection, Feinstein, Food, Sepsis, LinkedIn, Shock, Weatherall Institute of Molecular Medicine, PNAS, Medical research, Multimedia, Autoimmunity, National academy, Proceedings of the National Academy of Sciences of the United States of America, Pediatrics, Medicine, Biology, FDA, Blood pressure, Immune system, Mental health, Organ dysfunction, Hypotension, Institute, Patient, Pharmaceutical industry, Vaccine, MD

View the full release here: https://www.businesswire.com/news/home/20220829005673/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220829005673/en/
    Dr. Matthew D. Taylor, instructor in the Institute of Molecular Medicine at the Feinstein Institutes is co-principal investigator of the study.
  • (Credit: Feinstein Institutes)
    Sepsis is a common and fatal condition when the bodys regulatory control of the immune response to an infection is lost.
  • Researchers worldwide are beginning to unravel the underlying mechanisms of sepsis, said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes.
  • The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State.